# Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

> **NCT01444820** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital** · enrollment: 329 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** hypofractionation
- **RADIATION:** conventional

## Key facts

- **NCT ID:** NCT01444820
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-01
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01444820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01444820, "Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01444820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*